Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
| العنوان: | Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis |
|---|---|
| المؤلفون: | Willem F. Lems, Marijn Vis, Paul P. Tak, Lucien A. Aarden, Gerrit Jan Wolbink, Alexandre E. Voskuyl, Ben A. C. Dijkmans, Michael T. Nurmohamed, S.O. Stapel, Els R. de Groot |
| المساهمون: | Rheumatology, AII - Inflammatory diseases, AMS - Musculoskeletal Health, AMS - Tissue Function & Regeneration, Internal medicine, Landsteiner Laboratory, AII - Amsterdam institute for Infection and Immunity, Clinical Immunology and Rheumatology, General Internal Medicine |
| المصدر: | Wolbink, G J, Vis, M, Lems, W, Voskuyl, A E, de Groot, E, Nurmohamed, M T, Stapel, S, Tak, P P, Aarden, L & Dijkmans, B 2006, ' Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis ', Arthritis and Rheumatism, vol. 54, no. 3, pp. 711-5 . https://doi.org/10.1002/art.21671 Arthritis and Rheumatism, 54(3), 711-5. John Wiley and Sons Inc. Arthritis and rheumatism, 54(3), 711-715. John Wiley and Sons Inc. |
| سنة النشر: | 2006 |
| مصطلحات موضوعية: | musculoskeletal diseases, Male, medicine.medical_specialty, Immunology, Radioimmunoassay, Arthritis, Antibodies, Arthritis, Rheumatoid, Rheumatology, Internal medicine, medicine, Immunology and Allergy, Humans, Pharmacology (medical), biology, business.industry, Antibodies, Monoclonal, medicine.disease, Infliximab, Rheumatoid arthritis, Monoclonal, Antibody Formation, biology.protein, Female, Antibody, business, Rheumatism, medicine.drug |
| الوصف: | Objective Treatment of patients with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, may result in the formation of infliximab-specific IgG antibodies. This study evaluated the clinical significance of these antibodies in patients with rheumatoid arthritis (RA). Methods Antiinfliximab antibodies were measured using a newly developed radioimmunoassay in a cohort of 51 consecutive patients with RA treated with infliximab, with a followup of 1 year. In addition, serum infliximab levels were determined by enzyme-linked immunosorbent assay. The results were analyzed in relation to the clinical response to treatment according to the European League Against Rheumatism criteria. Results Antibodies against infliximab were detected in 22 patients (43%). Patients without detectable antiinfliximab antibodies (n = 29 [57%]) were significantly more often classified as responders (20 of 29 [69%]) compared with patients with detectable antiinfliximab antibodies (8 of 22 [36%]; P = 0.04). Three patients had an infusion-related allergic reaction, all of whom had detectable antiinfliximab antibodies. Conclusion In this study, nearly half of the RA patients treated with infliximab developed antiinfliximab antibodies within the first year of treatment. This seems to be clinically relevant, since development of antiinfliximab antibodies is associated with a reduced response to treatment. |
| اللغة: | English |
| تدمد: | 0004-3591 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::867e2791de2e7a1922dcddeee319f819 https://doi.org/10.1002/art.21671 |
| حقوق: | RESTRICTED |
| رقم الأكسشن: | edsair.doi.dedup.....867e2791de2e7a1922dcddeee319f819 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00043591 |
|---|